Anticytokine strategies for the treatment of septic shock: Relevance of animal models

Current Topics in Microbiology and Immunology

Volumn 216, Issue , 1996, Pages 298-311

  Heumann, D ^a   Glauser, M P ^a  

^a Department of Internal Medicine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BAY X 1351; MONOCLONAL ANTIBODY CB 0006; MONOCLONAL ANTIBODY MAK 195 F; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIAL INFECTION; CLINICAL TRIAL; DOSE RESPONSE; ENDOTOXEMIA; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SURVIVAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECEPTORS, TUMOR NECROSIS FACTOR; SHOCK, SEPTIC; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030322138     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-80186-0_14     Document Type: Article

References (38)

1. Abraham E, Wunderick R, Sliverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273. 934-941
2. Agosti JM, Fisher CJ, Opal SM, Lowry SF, Balk RA, Sadoff JC, the STNFR Sepsis Study Group (1994) Treatment of patients with sepsis syndrome with soluble TNF receptors (sTNFR) (Abstr) 34th Interscience Conference on Antimicrobial and Chemotherapy, p 65
3. Aiura K, Gelfand JA, Burke JF, Thompson RC, Dinarello CA (1993) Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits. Infect Immun 61: 3342-3350
4. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA (1991) A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice J Exp Med 173. 1029-1032
5. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA Jr, Smith DH (1991) Protection against endotoxin shock by a tumor necrosis factor receptor immunoadhesin Proc Natl Acad Sci USA 88 10535-19539
6. Bagby GJ, Plessala KJ, Wilson LA, Thompson KJ, Nelson S (1991) Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis J Infect Dis 163 83-88
7. Beutler B, Milsark IW, Cerami A (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229. 869-871
8. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, the Swiss-Dutch J5 Study Group (1990) Prognostic values of tumor necrosis factor/cachectin, interleukin-1, alpha-interferon and gamma-interferon in the serum of patients with septic shock J Infect Dis 161. 982-987
9. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17: 975-978
10. Echtenacher B, Falk W, Männel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145: 3762-3766
11. Emerson TE, Lindsey DC, Jesmok GJ, Duerr ML, Fournel MA (1992) Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock 38: 75-84
12. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG (1992) Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148: 2724-2730
13. Evans GF, Synder YM, Butler LD, Zuckerman SH (1989) Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ Shock 29: 279-290
14. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J (1994) Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180: 2173-2179
15. Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA (1991) Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys J Lab Clin Med 120: 574-588
16. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, Thompson RC, Lowry SF, Moldawer LL (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia J Clin Invest 89: 1551-1557
17. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RMH, Panacek EA, Vincent JL, Fouike GE, Warren EL, Gartrard C, Park G, Bodmer MW, Cohen J, Van der Linden C, Cross AS, Sadoff JC, the CB006 Sepsis Syndrome Study Group (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis Crit Care Med 21 318327
18. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC, for the Phase III rhIL-1ra Syndrome Study Group (1994a) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial JAMA 271: 1836-1843
19. Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA, the I1-ra Sepsis Syndrome Study Group (1994b) Initial evaluation of human recombinant interleukin-1 receptor anatagonist in the treatment od sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial Crit Care Med 22: 12-21
20. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 30: 279-292
21. Hinshaw LB, Emerson TE Jr, Taylor FB, Chang ACK, Duerr M, Peer GT, Flournoy DJ, White GL, Kosanke SD, Murray CK, Xu R, Passey RB, Fournel MA (1992) Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody J Trauma 33: 668-573
22. Jesmok G, Lindsey C, Duerr M, Fournel M, Emerson T (1992) Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine. Arn J Pathol 141: 1197-1207
23. Jin H, Yang R, Marsters SA, Bunting SA, Wurm FM, Chamow SM, Ashkenazi A (1994) Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody J Infect Dis 170: 1323-1326
24. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau GE, Piguet PF, Pointaire P, Vassalli P, Loetscher H (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality Eur J Immunol 21 2883-2886
25. Loetscher H, Angehrn P, Schlaeger EJ, Gentz R, Lesstauer W (1993) Efficacy of a chimeric TNFR-IgG fusion protein to inhibit TNF activity in animal models of septic shock. In. Levin J, Alving CR, Munford RS, Stütz PL (eds) Bacterial endotoxin: recognition and effector mechanisms Elsevier, Amsterdam, pp 455-462
26. Mancilla J, Garcia P, Dinarello CA (1993) The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun 61: 926-932
27. Martin RA, Silva AT, Cohen J (1993) Effect of anti-TNF-alpha treatment in an antibiotic treated murine model of shock due to Streptococcus pyogenes. FEMS Microbiol Lett 110: 175-178
28. Mathison JC, Wolfson E, Ulevitch RJ (1988) Participation of tumor necrosis factor in the mediation of bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81: 1925-1937
29. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Sremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TIMF antagonists. J Immunol 151: 1548-1561
30. Nassif X, Mathison JC, Wolfson E, Koziol JA, Ulevitch RJ, So M (1992) Tumour necrosis factor alpha antibody protects against lethal meningococcaemia Mol Microbiol 6: 591-597
31. Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348: 550-552
32. Opal SM, Cross AS, Sadoff JC, Collins HH, Kelly NM, Victor GH, Palardy GE, Bodmer MW (1991) Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest 88: 885-890
33. Schalg G, Redl H, Davies J, Haller I (1994) Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock 2: 10-18
34. Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental gram-negative shock J Infect Dis 162: 421-427
35. Teti G, Manucuso G, Tormasello F (1993) Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect Immun 61: 227-235
36. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664
37. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA (1991) A specific receptor antagonist for interleukin 1 prevents Escherichi coli-induced shock in rabbits FASEB J 5: 338-343
38. Zanetti, G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, Glauser MP, Baumgartner JD (1992) Cytokine production after intravenous of peritoneal Gram negative bacterial challenge in mice. Comparative protective efficacy of antibodies to TN and to LPS J Immunol 148: 1890-1897